12 March 2021 | 09:39am
StockMarketWire.com - Clinical AI technology company Sensyne has signed a £470,000 agreement with the Department of Health & Social Care (DHSC) to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The MagnifEye system is a software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different diagnostic tests, including lateral flow tests.
The agreement with the DHSC follows an announcement made by Sensyne on 09 February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Investegate | Company News | Corporate, London Stock Exchange, Regulatory News Headlines Sensyne signs government deal for covid tests study investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.